NOV 22, 2020 11:20 AM PST

Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD

WRITTEN BY: Annie Lennon

Researchers from St. Michael’s Hospital in Toronto have found that two synthetic cannabinoids available on prescription are linked to an increased risk of death and hospitalization in older patients with chronic obstructive pulmonary disease (COPD). 

For the study, the researchers looked at data from over 4,000 people with COPD in Ontario aged over 66 between 2006 and 2016. The patients were divided into two groups. One group used dronabinol or nabilone, synthetic cannabinoids with a similar chemical structure to THC often prescribed to treat COPD symptoms such as pain, difficulties falling asleep, and breathlessness. Meanwhile, the other group did not use these cannabinoids. 

In the end, the researchers found that while patients who used either cannabinoid were no more likely to be hospitalized for COPD or pneumonia than those in the other group, they were more likely to die of any cause. This was especially true for those who received high doses. All in all, these patients were 178% more likely to be hospitalized for COPD and pneumonia and 231% more likely to die of any cause. 

“Our study results do not mean that cannabinoid drugs should be never used among older adults with COPD,” says Dr. Nicholas Vozoris, lead author of the study. “Rather, our findings should be incorporated by patients and physicians into prescribing decision-making.”

While the researchers say that their findings show a negative association between older adults with COPD and synthetic cannabinoids, further research is needed to confirm their results. Nevertheless, as older adults are increasingly using cannabinoid-based drugs to treat COPD, the researchers say care should be taken when prescribing the drugs and for patients and physicians alike to have a clear understanding of their potential side effects. 

 

Sources: BMJMarijuana Business Daily

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
DEC 06, 2021
Cannabis Sciences
Benefits of Cannabis Tissue Culture
DEC 06, 2021
Benefits of Cannabis Tissue Culture
Cannabis cultivation has embraced tissue culture due to this approach’s many advantages. Tissue culture cultivatio ...
JAN 21, 2022
Cannabis Sciences
CBD inhalant effective in reducing glioblastoma tumors
JAN 21, 2022
CBD inhalant effective in reducing glioblastoma tumors
Researchers at Augusta University found that hat CBD inhalant can alter the lung microenvironment and subsequently inhib ...
JAN 28, 2022
Cannabis Sciences
Hemp Stalk Waste: A Novel Source of Eco-Friendly Energy with Electrical Applications?
JAN 28, 2022
Hemp Stalk Waste: A Novel Source of Eco-Friendly Energy with Electrical Applications?
Industrial hemp (Cannabis sativa L.) stalks are byproducts of cannabidiol (CBD) oil production that have thus far only b ...
FEB 03, 2022
Cannabis Sciences
A Standard THC Unit: Standardizing Dosage in Cannabis Industry & Research
FEB 03, 2022
A Standard THC Unit: Standardizing Dosage in Cannabis Industry & Research
A primary limitation of cannabis research thus far has been the inconsistent quantification of exposure to the plant&rsq ...
APR 14, 2022
Cannabis Sciences
Delta 10 is weird. Here's why.
APR 14, 2022
Delta 10 is weird. Here's why.
Delta 10 is weird. Here's why.
MAY 11, 2022
Cannabis Sciences
Legal Recreational Cannabis Reduces Prescription Drug Demand
MAY 11, 2022
Legal Recreational Cannabis Reduces Prescription Drug Demand
A research study published in Health Economics found a link between the availability of legal recreational cannabis, and ...
Loading Comments...